AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22723583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia
Number of subjects: 7287
Study 22723583 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemia
Number of subjects: 7287
Study 20012449 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study 20012449 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental (EXP)
Number of subjects: 16
Study 17196413 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment (0.2g, orally, q 12h for 1 month)
Number of subjects: 37
Study 17196413 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 37
Study 17196413 — intervention group
Group type: COMPARATOR
Intervention: Control (no theophylline treatment)
Number of subjects: 37
Study 15975303 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sinisan (SNS)
Number of subjects: 47
Study 15975303 — intervention group
Group type: COMPARATOR
Intervention: Cisapride (Control)
Number of subjects: 47
Study 12053585 — intervention group
Group type: EXPERIMENTAL
Intervention: one lancet-multiple pricks (multiple test method)
Number of subjects: 52
Study 12053585 — intervention group
Group type: COMPARATOR
Intervention: one lancet-one prick (single test method)
Number of subjects: 52
Study 10333620 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone (group A)
Number of subjects: 48
Study 10333620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cimetidine and levamisole (group B)
Number of subjects: 48
Study 8600545 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-3 (2.5 or 5.0 microg/kg/d) administered by subcutaneous injection for either 5 or 10 days following ABMT.
Number of subjects: 37
Study 8600545 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF (250 microg/m2/d as a 2-hour intravenous infusion) administered 24 hours after the last dose of rhIL-3.
Number of subjects: 37
Study 8600545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential cytokine therapy (rhIL-3 and rhGM-CSF) post-ABMT.
Number of subjects: 37
Study 2010560 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg
Number of subjects: 0
Study 2010560 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 0
Study 2010560 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 480 mg
Number of subjects: 0
Study 2010560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 0
Study 6952281 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 8
Study 6952281 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 8
Study 6952281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30996366 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 50
Study 30996366 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral Approach (ALA)
Number of subjects: 50
Study 28837727 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonant voice training using nasal consonants (n = 10)
Number of subjects: 30
Study 28837727 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw phonation (n = 10)
Number of subjects: 30
Study 28837727 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 30
Study 26309133 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth non-surgical treatment (FM-SRP)
Number of subjects: 38
Study 26309133 — intervention group
Group type: COMPARATOR
Intervention: Quadrant scaling (Q-SRP)
Number of subjects: 38
Study 26309133 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FM-SRP and Q-SRP
Number of subjects: 38
Study 26309133 — intervention group
Group type: EXPERIMENTAL
Intervention: FM-SRP
Number of subjects: 38
Study 23208319 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suctioning (CS)
Number of subjects: 15
Study 23208319 — intervention group
Group type: COMPARATOR
Intervention: Open suctioning (OS)
Number of subjects: 15
Study 21737129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Care intervention
Number of subjects: 203
Study 21737129 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 203
Study 21737129 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 203
Study 19564319 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic allopurinol (500 mg intravenously)
Number of subjects: 53
Study 19564319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19564319 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic allopurinol
Number of subjects: 53
Study 16972973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous frusemide 2 mg/kg
Number of subjects: 50
Study 16972973 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study 15610084 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, amoxycillin and metronidazole (7-day course)
Number of subjects: 92
Study 15610084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 11716834 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural movements
Number of subjects: 0
Study 11716834 — intervention group
Group type: COMPARATOR
Intervention: Scrambled displays
Number of subjects: 0
Study 9419915 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP trained nursing staff
Number of subjects: 25
Study 8329287 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg racemic ibuprofen (RAC)
Number of subjects: 50
Study 8329287 — intervention group
Group type: COMPARATOR
Intervention: 400 mg (S)-ibuprofen (S-IBU)
Number of subjects: 50
Study 2883047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 1738
Study 2883047 — intervention group
Group type: COMPARATOR
Intervention: TCu 200 Ag
Number of subjects: 1738
Study 31386103 — intervention group
Group type: EXPERIMENTAL
Intervention: CURRENT AS risk score (developed from a derivation set of N=849)
Number of subjects: 1274
Study 31386103 — intervention group
Group type: EXPERIMENTAL
Intervention: CURRENT AS risk score (validation set of N=425)
Number of subjects: 1274
Study 30130032 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders both 3 days and 1 day prior to the visit
Number of subjects: 54066
Study 30130032 — intervention group
Group type: COMPARATOR
Intervention: 3-day reminder
Number of subjects: 54066
Study 30130032 — intervention group
Group type: COMPARATOR
Intervention: 1-day reminder
Number of subjects: 54066
Study 30130032 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders both 3 days and 1 day prior to the visit (high risk patients)
Number of subjects: 54066
Study 30130032 — intervention group
Group type: COMPARATOR
Intervention: 3-day reminder (high risk patients)
Number of subjects: 54066
Study 30130032 — intervention group
Group type: COMPARATOR
Intervention: 1-day reminder (high risk patients)
Number of subjects: 54066
Study 27498606 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (5 days, 20 minutes per session, 2 mA)
Number of subjects: 30
Study 27498606 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (1 day real, 4 days sham)
Number of subjects: 30
Study 25546356 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)‐epicatechin
Number of subjects: 0
Study 25546356 — intervention group
Group type: EXPERIMENTAL
Intervention: procyanidin B1
Number of subjects: 0
Study 25546356 — intervention group
Group type: EXPERIMENTAL
Intervention: polymeric procyanidins
Number of subjects: 0
Study 25546356 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota metabolism
Number of subjects: 0
Study 22944077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesser tuberosity osteotomy (LTO)
Number of subjects: 87
Study 22944077 — intervention group
Group type: COMPARATOR
Intervention: Subscapularis peel
Number of subjects: 87
Study 19787380 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion set (500-cc solution bag with gravity-driven delivery)
Number of subjects: 27
Study 19787380 — intervention group
Group type: COMPARATOR
Intervention: Infusion pump
Number of subjects: 27
Study 18401766 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucerna
Number of subjects: 203
Study 18401766 — intervention group
Group type: COMPARATOR
Intervention: Fresubin
Number of subjects: 203
Study 15937041 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal secretin applied daily in ointment form for 4 weeks
Number of subjects: 15
Study 15937041 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied daily in ointment form for 4 weeks
Number of subjects: 15
Study 15344899 — intervention group
Group type: EXPERIMENTAL
Intervention: Prerandomization computerized tomography (CT) scans
Number of subjects: 0
Study 10987150 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (active and passive jaw movement exercises, correction of body posture, and relaxation techniques)
Number of subjects: 30
Study 10987150 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 30
Study 10987150 — intervention group
Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 30
Study 8988067 — intervention group
Group type: EXPERIMENTAL
Intervention: Watercress + Acetaminophen
Number of subjects: 7
Study 1455306 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 150 micrograms subcutaneously every 8 hours
Number of subjects: 21
Study 1455306 — intervention group
Group type: COMPARATOR
Intervention: Saline solution subcutaneously every 8 hours
Number of subjects: 21
Study 1455306 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide and Saline solution
Number of subjects: 21
Study 6365349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 126
Study 6365349 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 126
Study 30858012 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine-ER
Number of subjects: 113
Study 30858012 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 113
Study 29933559 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt fermented with Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1
Number of subjects: 49
Study 29933559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 26959482 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 1,000 IU daily for 6 months
Number of subjects: 96
Study 25149431 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara (MVA) vaccine administered by subcutaneous injection at Week 0 and 4
Number of subjects: 60
Study 25149431 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara (MVA) vaccine
Number of subjects: 60
Study 25149431 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60
Study 22240180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative music added to routine pain control measures (ibuprofen and paracervical block)
Number of subjects: 101
Study 22240180 — intervention group
Group type: COMPARATOR
Intervention: Routine pain control measures only (ibuprofen and paracervical block)
Number of subjects: 101
Study 20416451 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg oral tablets daily for one month
Number of subjects: 70
Study 20416451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17687689 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg/day
Number of subjects: 75
Study 17687689 — intervention group
Group type: EXPERIMENTAL
Intervention: doxepine 10 mg/day
Number of subjects: 75
Study 17687689 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxyzine 25 mg/day
Number of subjects: 75
Study 16329418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer (3M Dental Products)
Number of subjects: 30
Study 16329418 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000 Compomer (3M Dental Products)
Number of subjects: 30
Study 16329418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract AP (Dentsply DeTrey)
Number of subjects: 30
Study 16329418 — intervention group
Group type: EXPERIMENTAL
Intervention: Valux Plus (3M Dental Products)
Number of subjects: 30
Study 16881161 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant intervention
Number of subjects: 0
Study 16881161 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9495433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg) administered 1 min before intubation
Number of subjects: 170
Study 9495433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg) administered 3 min before intubation
Number of subjects: 170
Study 9495433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg) administered 5 min before intubation
Number of subjects: 170
Study 9495433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg) administered 10 min before intubation
Number of subjects: 170
Study 9495433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 170
Study 7787368 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Structure Regulation (law enacted in 1992)
Number of subjects: 0
Study 2668060 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days treatment with amoxycillin (1.5 g/day)
Number of subjects: 10909
Study 2668060 — intervention group
Group type: COMPARATOR
Intervention: 10 days therapy (750 mg amoxycillin/day)
Number of subjects: 10909
Study 1213890 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with estrogen in an alcoholic vehicle (0.05% dienestroldiacetate) applied daily on the scalp skin
Number of subjects: 30
Study 1213890 — intervention group
Group type: COMPARATOR
Intervention: Corresponding preparation without estrogen (control group)
Number of subjects: 30
Study 1213890 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with estrogen
Number of subjects: 30
Study 31091575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose remifentanil (Group L)
Number of subjects: 90
Study 31091575 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose remifentanil (Group H)
Number of subjects: 90
Study 31091575 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose remifentanil with gradual withdrawal (Group G)
Number of subjects: 90
Study 31091575 — intervention group
Group type: COMPARATOR
Intervention: Control (Group H)
Number of subjects: 90
Study 27152677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 802
Study 27152677 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 802
Study 25520333 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention protocol (manual tooth/gum brushing plus 0.12% chlorhexidine oral rinse, twice per day, plus upright positioning during feeding)
Number of subjects: 834
Study 25520333 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 834
Study 25520333 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention protocol
Number of subjects: 834
Study 23930160 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage (10-15 min, 3 times a week for 10 sessions)
Number of subjects: 50
Study 23930160 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage, relaxed in the same environment)
Number of subjects: 50
Study 21777835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercoat gel (polyethylene oxide-sodium carboxymethylcellulose) applied intrauterinely during hysteroscopic surgery
Number of subjects: 110
Study 21777835 — intervention group
Group type: COMPARATOR
Intervention: Control group (hysteroscopic surgery only)
Number of subjects: 110
Study 18570693 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise (100 min at 30 % of peak oxygen consumption; net energy expenditure 1.04 (sem 0.01) MJ) plus mild energy intake restriction (1.39 (sem 0.22) MJ)
Number of subjects: 8
Study 18570693 — intervention group
Group type: COMPARATOR
Intervention: Control (resting coupled with isoenergetic feeding)
Number of subjects: 8
Study 17039510 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold-coated stents
Number of subjects: 731
Study 17039510 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stents
Number of subjects: 731
Study 15105064 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG IUS
Number of subjects: 200
Study 15105064 — intervention group
Group type: COMPARATOR
Intervention: Oral Contraceptives (OCs)
Number of subjects: 200
Study 12116891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg caplets and i.v. argatroban 1.5 micrograms/kg/min
Number of subjects: 35
Study 12116891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg/hr and i.v. argatroban 1.5 micrograms/kg/min
Number of subjects: 35
Study 12116891 — intervention group
Group type: COMPARATOR
Intervention: Oral digoxin 0.375 mg/day and i.v. argatroban 2 micrograms/kg/min
Number of subjects: 35
Study 9525449 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg twice daily
Number of subjects: 16
Study 9525449 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg once daily
Number of subjects: 16
Study 9525449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7712753 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (parenteral cefotaxime, oral and enteral polymyxin E, amphotericin B, tobramycin)
Number of subjects: 1528
Study 7712753 — intervention group
Group type: COMPARATOR
Intervention: No selective decontamination
Number of subjects: 1528
Study 2568299 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg
Number of subjects: 16
Study 2568299 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 16
Study 2568299 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 16
Study 2568299 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 363631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg/day)
Number of subjects: 38
Study 363631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 27271374 — intervention group
Group type: EXPERIMENTAL
Intervention: MitiiTM training (20 weeks, 30 minutes/day, six days/week, total 60 hours)
Number of subjects: 60
Study 27271374 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (waitlisted for 20 weeks)
Number of subjects: 60
Study 25806674 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25% carbachol plus 0.2% brimonidine eye drops
Number of subjects: 48
Study 25806674 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 48
Study 23748458 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy at a dose of 4 J/cm²
Number of subjects: 21
Study 23748458 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling with 2% lidocaine injection
Number of subjects: 21
Study 23748458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study 20547464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion trial (HIT; 47.5°C) of 2 min duration
Number of subjects: 24
Study 20547464 — intervention group
Group type: COMPARATOR
Intervention: Inter-digital web pinching (IWP; 15N)
Number of subjects: 24
Study 18954363 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine-tryptophan-ketoglutarate (HTK)
Number of subjects: 68
Study 18954363 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW)
Number of subjects: 68
Study 17885992 — intervention group
Group type: EXPERIMENTAL
Intervention: Idea improvement
Number of subjects: 0
Study 17885992 — intervention group
Group type: COMPARATOR
Intervention: Idea imagery
Number of subjects: 0
Study 17885992 — intervention group
Group type: EXPERIMENTAL
Intervention: Source-monitoring test
Number of subjects: 0
Study 15136680 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 557
Study 15136680 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 557
Study 15136680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study 11480162 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect imagery with external imagery
Number of subjects: 50
Study 11480162 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect imagery with internal imagery
Number of subjects: 50
Study 11480162 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect imagery with external imagery
Number of subjects: 50
Study 11480162 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect imagery with internal imagery
Number of subjects: 50
Study 11480162 — intervention group
Group type: COMPARATOR
Intervention: Control group (no manipulation)
Number of subjects: 50
Study 9643685 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stent placement (group I, n=143)
Number of subjects: 279
Study 9643685 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty followed by selective stent placement (group II, n=136)
Number of subjects: 279
Study 8172700 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular training (VT)
Number of subjects: 0
Study 8172700 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 0
Study 8172700 — intervention group
Group type: EXPERIMENTAL
Intervention: VT with medication
Number of subjects: 0
Study 8172700 — intervention group
Group type: EXPERIMENTAL
Intervention: VT without medication
Number of subjects: 0
Study 31863245 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Poincaré analysis using Poincaré‐index20‐30 Hz combined with Poincaré‐index0.5‐47 Hz
Number of subjects: 30
Study 31863245 — intervention group
Group type: COMPARATOR
Intervention: Original Poincaré‐index0.5‐47 Hz
Number of subjects: 30
Study 30862667 — intervention group
Group type: EXPERIMENTAL
Intervention: JT010 (TRPA1 agonist)
Number of subjects: 16
Study 30862667 — intervention group
Group type: EXPERIMENTAL
Intervention: A-967079 (TRPA1 antagonist)
Number of subjects: 16
Study 30862667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27590442 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of satisfaction with care coordination and quality
Number of subjects: 23470